6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
A series of 6alpha-alkyl-substituted analogues of chenodeoxycholic acid (CDCA) were synthesized and evaluated as potential farnesoid X receptor (FXR) ligands. Among them, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) was shown to be a very potent and selective FXR agonist (EC(50) = 99 nM) and to be endowed with anticholeretic activity in an in vivo rat model of cholestasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A bile acid receptor (FXR) agonist has reached the market since this programme started: obeticholic acid (Ocaliva), which was discovered by GSK in collaboration with the University of Perugia51 and subsequently developed by Intercept Pharmaceuticals.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [51]
In the citing paper
“OCA is a farnesoid X receptor (FXR) agonist that is 100 times more potent than the endogenous ligand, chenodeoxycholic acid.(156)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [156]
In the citing paper
“Obeticholic acid has approximately 100 times greater potency in activating FXR than chenodeoxycholic acid. 11”
From A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis (2016) · cites this paper as [11]
In the citing paper
“Obeticholic acid is a selective farnesoid X receptor (FXR) agonist that is derived from the bile acid chenodeoxycholic acid, the endogenous FXR ligand.”
From A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis (2016) · cites this paper as [11]
In the citing paper
“OCA, a 6α-ethyl derivate of chenodeoxycholic acid, is a steroidal FXR agonist (still maintaining its BA structure) and first-in-class therapeutic FXR ligand.94”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [94]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Self-citationNuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis
Goodwin, B., Jones, S. A., Price, R. R., Watson, M. A., McKee, D. D., Moore, L. B., Galardi, C., Wilson, J. G., Lewis, M. C., Roth, M. E., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00051-4 · Cited by 1,940
Self-citationTargeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR
Wang, H., Chen, J., Hollister, K., Sowers, L. C., & Forman, B. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80348-2 · Cited by 1,636
Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators
McKenna, N. J., & O'Malley, B. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00641-4 · Cited by 1,463
The Continuing Importance of Bile Acids in Liver and Intestinal Disease
Hofmann, A. F. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.22.2647 · Cited by 982
Modulation of Polyketide Synthase Activity by Accessory Proteins During Lovastatin Biosynthesis
Kennedy, J., Auclair, K., Kendrew, S. G., Park, C., Vederas, J. C., & Richard Hutchinson, C. (1999) · Science · doi:10.1126/science.284.5418.1368 · Cited by 654
Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR
Maloney, P. R., Parks, D. J., Haffner, C. D., Fivush, A. M., Chandra, G., Plunket, K. D., Creech, K. L., Moore, L. B., Wilson, J. G., Lewis, M. C., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0002127 · Cited by 527
Self-citation
Research works printed but not linked: 3
- Mangelsdorf D. J., 1995, Cell, 83, 850
- Forman B. M., 1995, Cell, 81, 693
- Lu T. T., 2000, Mol. Cell, 6, 515
Cited by
Items 701–793 of 793
Emerging therapeutic targets for primary sclerosing cholangitis
Kalani, A., Tabibian, J. H., & Lindor, K. D. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1490643
“fibrogenesis and bile acid biosynthesis pathways [56].”
FXR and its ligands inhibit the function of platelets
Moraes, L. A., Unsworth, A. J., Vaiyapuri, S., Ali, M. S., Sasikumar, P., Sage, T., Flora, G. D., Bye, A. P., Kriek, N., Dorchies, E., et al. (2016)
Primary biliary cholangitis: an update on treatment
Bibi, F. (2018) · Gastrointestinal Nursing · doi:10.12968/gasn.2018.16.sup10.s10
Fiorucci, S. (2007) · Wiley eBooks · doi:10.1002/9780470691861.ch3d
Self-citationCharacterizing a Novel Ligand for the Farnesoid X Receptor using Transgenic Zebrafish
Costa, S. (2018) · TSpace (University of Toronto)
Hakim, A., Patwardhan, V. R., & Bonder, A. (2020) · Clinical Liver Disease · doi:10.1002/cld.964
Kleemann, A. (2021) · Ullmann's Encyclopedia of Industrial Chemistry · doi:10.1002/14356007.a12_143.pub2
A Novel Telescoped Kilogram-Scale Process for Preparation of Obeticholic Acid
Li, C., Wang, C., Guo, C., Lv, B.-H., & Luo, Y.-F. (2021) · Pharmaceutical Fronts · doi:10.1055/s-0041-1731757
Development of liver organoids from NASH model mice and their application to drug discovery
Yamamoto, H., Usui, T., & Sasaki, K. (2021) · Folia Pharmacologica Japonica · doi:10.1254/fpj.21027
Nuclear Hormone Receptor Medicinal Chemistry
Cheng, P. T. W., Kick, E. K., & Mukherjee, R. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc191.pub2
(2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00485_3.x
(2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00485.x
Wang, Y., Chen, W., Chen, X., & Huang, W. (2010) · Springer eBooks · doi:10.1007/978-90-481-3303-1_12
Claudel, T., Sturm, E., Staels, B., & Kuipers, F. (2003) · CRC Press eBooks · doi:10.3109/9780203492444-8
Khakoo, N. S., & Levy, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00039-4
Regulation of Hepatobiliary Transporters During Liver Injury
Aleksunes, L. M., Ghanem, C. I., & Manautou, J. E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00268-0
Lavoie, A.-A., Thérien, A., Silva, A. J., Paré, E., Cieślak, A., Gagnon, W., Desjardins, C., Verreault, M., Trottier, J., Vohl, M., et al. (2025) · Biochemical Journal · doi:10.1042/bcj20253113
Dyslipidemic SPTLC3 Integrates Bile Acid-FXR Signaling with Sphingolipid Remodeling in MASLDPreprint
Visentin, M., Gai, Z., Kovilakath, A., Luca, F. D., Panteloglou, G., Othman, A., Liu, M., Barone, F., Garrelfs, I., Verheij, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.25.672208
“2D) and a relatively strong FXR agonist (EC 50 = 0.1 μM) [71].”
InfluentialRazori, M. V., Hillotte, G. L., Martín, P. L., Barosso, I. R., Basiglio, C. L., Ruiz, M. L., & Roma, M. G. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111393 · Cited by 1
In Silico Study of Obeticholic Acid Analogs as FXR Agonists
Seijas, J. A., Vázquez‐Gómez, S., Meijide, F., & Vázquez-Tato, M. P. (2025) · doi:10.3390/ecsoc-29-27271
“The 6 α -ethyl group may reside in a hydrophobic cavity within the ligand-binding domain of FXR, a key structural element for FXR potency [14].”
da Silva, M. A. E., Camargo, P. G., Lima, C. H. D. S., Rodrigues, C. R., Albuquerque, M. G., & Rezende, C. M. (2026) · Scientific Reports · doi:10.1038/s41598-026-37519-6
“Therefore, for FXR, obeticholic acid (OCA), also known as 6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist (EC 50 = 99 nM) 33 , was considered.”
Zheng, X., Zhang, Z., Jiao, X., Mu, M., Liu, A. Y., Huang, Y., Wu, W., Liao, C., Jiang, Y., Liang, W., et al. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109721
Influence of bile acids metabolism on hepatic immunity in mice
Guinot, V. (2022) · theses.fr (ABES) · doi:10.70675/b69bb11eza30fz4874z9af2za6e31b2d5ad8
Identification of a novel HNF4α agonist regulating abnormal metabolism
Wang, T., Wei, C., Li, J., Zhao, X., Wang, K., Peng, X., Dou, X., Liu, Y., Wang, C., & Jiao, N. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118864
Chang, X., Olthof, P. B., Jin, H., Chau, S., Soons, Z. I. T. A., van Eijk, H. M. H., van Golen, R. F., van Gulik, T. M., Jansen, P. L. M., Damink, S. W. M. O., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119368
Zhang, Z., Zheng, X., Dong, C., Li, P., Lin, Y., Sun, Z., Li, W., Liu, X., Li, J. J., Li, S., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03220 · Cited by 2
Modulating the human gut microbiome-host system: a new drug discovery paradigm
Colmenarejo, G. (2026) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2026.1898583
The enabling power of chemical probes: examples from the nuclear hormone receptor field
Willson, T. M., & Merk, D. (2026) · Essays in Biochemistry · doi:10.1042/ebc20260016
Self-citationSanai, F. M., Alghamdi, A. S., Khathlan, A. A., Qutub, A. A., Quraishi, H. A., Alghamdi, M., ALZaabi, M. E. H., Mawardi, M., Altarrah, M. Y., Alnahdi, N., et al. (2026) · Cureus · doi:10.7759/cureus.113526
Zou, J., Kan, Y., Song, W., Song, S., Huang, D., Liu, J., & Guo, F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1847544
Zhu, H., Chen, H., Gong, Q., Chen, Z., Zhang, C., Xu, J., & Wang, T. (2026) · Medicinal Research Reviews · doi:10.1002/med.70116
BindingDB Entry 50037531: Farnesoid X receptor: from structure to potential clinical applications.
BindingDB (2012) · UC San Diego · doi:10.7270/q2n29xq6
BindingDB Entry 50001047: A novel intestinal-restricted FXR agonist.
BindingDB (2020) · UC San Diego · doi:10.7270/q2c82csd
BindingDB Entry 50018517: Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor.
BindingDB (2024) · UC San Diego · doi:10.7270/q2ff3xjm
BindingDB (2008) · UC San Diego · doi:10.7270/q21r6nsz
BindingDB (2022) · UC San Diego · doi:10.7270/q23j3hr8
BindingDB Entry 50017303: Discovery of (
BindingDB (2023) · UC San Diego · doi:10.7270/q2k35zr8
BindingDB (2012) · UC San Diego · doi:10.7270/q2q52q5j
BindingDB Entry 50011222: Design and Structural Optimization of Dual FXR/PPARδ Activators.
BindingDB (2021) · UC San Diego · doi:10.7270/q21r6v3g
BindingDB Entry 3280: Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist.
BindingDB (2009) · UC San Diego · doi:10.7270/q2ft8jch
BindingDB Entry 50049323: Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery.
BindingDB (2019) · UC San Diego · doi:10.7270/q2t43wdq
BindingDB (2024) · UC San Diego · doi:10.7270/q2377f4s
BindingDB (2015) · UC San Diego · doi:10.7270/q2z89dz0
BindingDB (2024) · UC San Diego · doi:10.7270/q2445rqn
BindingDB (2013) · UC San Diego · doi:10.7270/q27d2w7k
BindingDB Entry 50012712: A New FXR Ligand Chemotype with Agonist/Antagonist Switch.
BindingDB (2022) · UC San Diego · doi:10.7270/q2ns0zm3
BindingDB (2021) · UC San Diego · doi:10.7270/q2dj5jxg
BindingDB Entry 50014932: Second-Generation Dual FXR/sEH Modulators with Optimized Pharmacokinetics.
BindingDB (2023) · UC San Diego · doi:10.7270/q2wm1j9x
BindingDB Entry 50000683: Nonacidic Farnesoid X Receptor Modulators.
BindingDB (2019) · UC San Diego · doi:10.7270/q2736tbh
BindingDB Entry 50044076: Some non-conventional biomolecular targets for diamidines. A short survey.
BindingDB (2015) · UC San Diego · doi:10.7270/q2n29zgg
Metadata
- Authors
- Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M.
- Affiliations
- University of Perugia (IT)
- Corresponding author
- Pellicciari, Roberto
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2002-07-20
- Volume
- 45
- Issue
- 17
- Pages
- 3569-3572
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2049515100
- Cited by
- 743
- References
- 15
- Citations by year
- 2026: 20 · 2025: 33 · 2024: 32 · 2023: 33 · 2022: 46 · 2021: 47 · 2020: 54 · 2019: 46 · 2018: 52 · 2017: 60 · 2016: 49 · 2015: 38 · 2014: 35 · 2013: 27 · 2012: 31
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- farnesoid X receptor agonist, cholestasis, bile acid synthesis inhibition, receptor selectivity
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Anticholesteremic Agents, Cell Line, Chenodeoxycholic Acid, Cholestasis, DNA-Binding Proteins, Humans, Ligands, Liver, Structure-Activity Relationship, Transcription Factors, Rats, Wistar, Receptors, Cytoplasmic and Nuclear, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.